Avatrombopag Maleate, also known as Doptelet® in the United States, is a thrombopoietin receptor agonist used primarily for the treatment of thrombocytopenia. Below is a detailed introduction to Avatrombopag Maleate:
Basic Information
English Name: Avatrombopag Maleate
Common Name: Avatrombopag
Chemical Name: 1-[3-Chloro-5-[[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]amino]carbonyl]-2-pyridinyl]piperidine-4-carboxylic acid, (2Z)-butenedioic acid (1:1)
CAS Number: 677007-74-8
Molecular Weight: 765.72700
Development and Approval
It was approved by the U.S. Food and Drug Administration (FDA) on May 21, 2018, for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.
The drug has also received orphan drug designation from the FDA for the treatment of chronic immune thrombocytopenia (ITP), and clinical trials are ongoing.
Pharmacological Action
Avatrombopag Maleate is a thrombopoietin receptor agonist that stimulates the proliferation of bone marrow progenitor cells and differentiation of megakaryocytes, leading to increased platelet production.
It does not compete with thrombopoietin for receptor binding but binds to a different site, exhibiting an additive effect with endogenous ligands in promoting platelet production.
In summary, Avatrombopag Maleate is an effective thrombopoietin receptor agonist used to treat thrombocytopenia.
